OP

OptimizeRx Corp

OPRX
Accountable AI Logo

OptimizeRx Corp AI Insights

Informational only. Not investment advice.
As of 2025-12-11

Snapshot

  • Goodwill of 70.9M is 58% of equity and 66% of intangibles (113.3M) - acquisition-heavy model with impairment risk if growth stalls[Goodwill]
  • FCF TTM of 11.6M vs net income of 34K - earnings near zero but cash generation strong; interest expense (5.6M) consuming operating profit[Free Cash Flow TTM]
  • Revenue 3Y CAGR of 20% vs industry median 5.4% - outpacing peers but P/E of 1,403x signals market pricing in massive future growth[Total Revenue 3Y Growth]

Watch Triggers

  • Interest Expense TTM: Rises above 6.5M or interest coverage falls below 1.0xAlready consuming most operating income; any increase threatens FCF
  • Goodwill: Any impairment charge or acquisition adding to 70.9M balance58% of equity; impairment would devastate book value
  • Total Revenue 3Y Growth: Falls below 15% CAGRValuation requires sustained 20%+ growth; deceleration reprices stock

Bull Case

Gross margin TTM 65.3% vs industry 43.7% - software-like economics with minimal capex (258K TTM) enables 10.6% FCF yield on EV

Gross Margin TTMFree Cash Flow TTMCapital Expenditure TTM

20% revenue CAGR (3Y and 5Y) in healthcare IT niche with operating leverage - operating margin 6.2% vs industry 2% shows scale benefits emerging

Total Revenue 3Y GrowthOperating Margin TTM

Bear Case

P/E of 1,403x and P/B of 30.5x require flawless execution; tangible book value only 9M vs 273M market cap - 96% of value is intangible

PE RatioPB RatioTangible Book Value

Net income TTM of 34K on 109.5M revenue (0.03% margin) - interest burden and amortization consuming operating profits entirely

Net Income TTMNet Margin TTMInterest Expense TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
35%

Leverage OPRX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

FCF conversion will compress as interest costs rise or revenue growth decelerates

1-3ymed
  • Interest expense 5.6M TTM on 28.6M debt (19.6% effective rate)
  • Operating income 6.8M barely covers interest
  • Revenue growth must sustain 20%+ to maintain coverage
Interest coverage ratio ~1.2x (EBIT 7.3M / Interest 5.6M)FCF 11.6M masks near-zero net incomeDebt/equity 0.23 but high-cost debt
Valuation Context
Caveats

Public Strategies Rankings

See how OptimizeRx Corp ranks across different investment strategies.

Leverage OPRX's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2025 Accountable Finance, Inc. All rights reserved.